Background Progressive respiratory failure is the primary cause of death in the coronavirus
disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of …

Background Antivirals are needed to combat the COVID-19 pandemic, which is caused by
SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS-CoV-…

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with vascular …

The rationale of α1-antitrypsin (AAT) augmentation therapy to treat progressive emphysema
in AAT-deficient patients is based on inhibition of neutrophil elastase; however, the benefit …

Right ventricular (RV) heart failure is the leading cause of death in pulmonary arterial
hypertension (PAH). Peroxisome proliferator–activated receptor γ (PPARγ) acts as a …

Pulmonary arterial hypertension (PAH) is a debilitating disease with a high mortality rate. A
hallmark of PAH is plexiform lesions (PLs), complex vascular formations originating from …

BMP2 and TGFβ1 are functional antagonists of pathological remodeling in the arteries, heart,
and lung; however, the mechanisms in VSMCs, and their disturbance in pulmonary arterial …

We recently showed that SARS-CoV-2 infection leads to angiocentric inflammation in COVID-19-induced
respiratory failure, with a greater number of ACE2-positive endothelial cells …

Multiplexed antibody-based imaging enables the detailed characterization of molecular and
cellular organization in tissues. Advances in the field now allow high-parameter data …

Background The histomorphological changes of lung damage in severe coronavirus disease
2019 (COVID-19) have not yet been adequately characterized. In this article, we describe …